MOMA Therapeutics’ $150 Million Series B Financing

Goodwin Procter advised MOMA Therapeutics on the deal.

MOMA Therapeutics announced its completion of a $150 million Series B Financing.

MOMA Therapeutics is a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease.

MOMA’s drug discovery platform exploits a key vulnerability inherent to all enzymes in the molecular machine class: their dependence on well-coordinated, stepwise changes in conformation. By focusing this platform on disease-causing proteins, MOMA aims to develop precision medicines for patients with significant unmet medical needs. Proceeds from the financing will be used to further develop product opportunities and advance a rich pipeline of precision oncology programs.

The Goodwin team was led by Gaby Morales-Rivera (Picture), Kingsley Taft, Kaitlin Carragher, and Joshua Mathew.

Involved fees earner: Kaitlin Carragher – Goodwin Procter; Josh Mathew – Goodwin Procter; Gabriela Morales-Rivera – Goodwin Procter; Kingsley Taft – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: MoMa Therapeutics ;

Martina Bellini

Author: Martina Bellini